Raise closed, search for fresh raises on Seedstage

Huntington, NY

Advancing the development of anti-inflammatory therapies to improve global health outcomes.

• Mission: Transforming the treatment of inflammation with innovative, safe, and affordable therapies that target the root causes of inflammatory diseases.  
• Innovation: Repurposing FDA-approved small molecules to develop effective anti-inflammatory treatments that focus on prevention rather than merely masking symptoms.  
• Clinical Advancements: With a portfolio of 11 assets, several nearing Phase 2 clinical trials, Sen-Jam is on track to advance treatments for conditions linked to inflammation, such as opioid use disorder and viral respiratory infections.  
• Market Opportunity: Positioned to capture a share of the rapidly growing $217 billion anti-inflammatory therapy market, Sen-Jam’s products aim to enhance health outcomes globally.  
• Leadership: Led by a team of experienced professionals, Sen-Jam brings together expertise across pharmaceuticals, healthcare, and biotechnology to drive innovation in inflammation treatment.  
• Strategic Partnerships: Focused on fostering collaborations to increase the accessibility and development of treatments that can improve patient outcomes and address global health challenges.  

Sen-Jam Pharmaceuticals is dedicated to transforming the treatment of inflammation and the broader pharmaceutical landscape by developing innovative, safe, and affordable anti-inflammatory products. The company focuses on repurposing FDA-approved small molecules to create effective therapies that prevent inflammation rather than simply masking symptoms.

With a portfolio of 11 assets, including several nearing pivotal Phase 2 clinical trials, Sen-Jam aims to address the root causes of various diseases linked to inflammation, which affects billions globally. The company’s mission is not only to improve health outcomes but also to ensure that treatments are accessible and tailored to individual needs.

As part of its growth strategy, Sen-Jam is seeking investment to advance its clinical trials and to solidify its position in the burgeoning $217 billion market for anti-inflammatory therapies. By engaging with investors, Sen-Jam aspires to create a new category within the pharmaceutical industry that emphasizes prevention and human-centric care, ultimately enhancing the quality of life for those suffering from inflammatory conditions.

This initiative represents a commitment to innovation and a vision for a healthier future, where the impact of inflammation on global health is significantly reduced.

Company Info

Sen-Jam Pharmaceutical develops innovative treatments for inflammation-related health issues, focusing on opioid use disorder and viral infections.

Sen-Jam Pharmaceutical is a company dedicated to addressing significant health issues related to inflammation, particularly in the context of opioid use disorder, viral respiratory infections, and alcohol-related ailments. By utilizing patented technology and the 505(b)2 regulatory pathway, the company aims to develop innovative treatments that can enhance patient outcomes. Their therapeutic pipeline includes repurposed small molecules that combine effective and safe agents to create new solutions for pain relief. The company also focuses on forming strategic partnerships to foster development and accessibility of their products. Sen-Jam’s initiatives are positioned to tackle widespread issues such as the opioid crisis, the impact of COVID-19, and the negative effects of alcohol consumption, including hangovers. They emphasize a commitment to health equality and the importance of safe, affordable medication. Their leadership team comprises experienced professionals from various fields, all striving to improve healthcare delivery and patient care through novel pharmaceutical solutions.